Foamy virus infection in animals and humans does not cause disease
Foamy viruses are the only members of the Spumaretroviruses, one of two families of the Retroviridae, the other and much larger family being the Orthoretroviruses (ORV). From those, the viral vectors that have been most exploited in trials are murine leukemia virus (MLV) (a gammaretrovirus) and human immunodeficiency virus (HIV-1) and EIAV (both lentiviruses). The wild-type viruses from which these vectors are derived all cause disease, whereas foamy viruses do not. In the infected host, active foamy virus replication seems to be restricted to the oral mucosa, 1 suggesting that transmission in animals occurs by bites and other wounds. In the wild, monkeys are commonly infected with their respective foamy virus and in captivity as many as 100% can test positive. When Hahn's group looked for evidence of foamy virus infection in wild equatorial African chimpanzees by testing for antibody and nucleic acid in fecal samples, they confirmed a prevalence of between 44 and 100%. 2 Morozov et al. 3 found that 12 of 14 free living chimpanzees in Tai National Park (Cô te d'Ivoir) were Semliki forest virus (SFV) infected. The sensitive assays used by Jones-Engel et al. 4 found, not only that more than 92% of wild non-human primates were SFV positive in Thailand but that some had already been seroconverted by the age of 3. Engel et al. 5 reported 88% of Gibraltar's macaques to be SFV positive. Thus, foamy virus infection is widespread in non-human primates.
Superinfection of animals with different foamy virus strains is possible, as shown by inter-species transmission of SFV in chimpanzees that prey on colobus monkeys. In addition to their own strain, the chimpanzees were also infected with SFV specific for colobus monkeys. 6 Despite having been described in a variety of mammalian species, including non-human primates, cats, cows and horses, sea lions and hamsters, in which 
Prospects
Novel approaches to areas that have hitherto proved to be technically challenging, such as: producing packaging cell lines. defining the cellular receptor. increasing vector titre further. Reversal of a single gene defect in a canine model may lead to clinical trial of a similar clinical condition in humans. Reversal of further single-gene defects.
they cause life-long persistent infections and, despite intensive searching, no natural reservoir for foamy virus in humans has ever been documented. Accidental zoonotic infections, however, are not unknown for people in close contact with non-human primates, such as animal handlers and bush meat traders. 7 Investigating prototype foamy virus (PFV) infection in Asians, Jones-Engels et al. 8 identified 2.6% positivity (8 out of 305). The virus persists in peripheral blood lymphocytes for over 20 years, suggesting a capability for long-term gene expression in the case of PFV-derived vectors. Infected humans do not transmit the virus horizontally. However, when blood of an SFV-infected monkey was transfused into an uninfected animal, molecular evidence of infection became obvious after 8 weeks, with seroconversion 1 week later, confirming that foamy viruses can be transmitted through blood products. 9 In marked contrast to the cytopathic effect induced in vitro (it is the infection-induced vacuolation that gives cells their 'foamy' appearance), no pathology has been assigned to foamy virus infection in any host. Early papers attempting to link infection with a variety of disease states have not withstood the test of time.
Although it is true to say that the effect of foamy virus infection in humans under conditions of immunosuppression is not known, it is known that primates and cats dually infected with immunodeficiency viruses and foamy viruses have no different a profile from those that are foamy virus free. There is no evidence from many studies carried out over the last decade in both animals and humans that foamy virus infection causes any clinical condition or deleterious effects.
Foamy virus replication is different from that of other retroviruses
Foamy viruses have a typical retrovirus morphology with the distinguishing feature of extra long (15 nm) spikes by which they gain entry to a wide variety of cell types in vitro. Indeed, it is challenging to find a cell line refractory to PFV infection, something that has consistently hampered identification of their cellular receptor. However, it is known that viruses enter the cell at the low pH of the late endosome and travel along the microtubules towards the microtubule-organizing center. The first molecularly cloned isolate originated from a cell culture of a nasopharyngeal carcinoma patient and was designated, the human spumaretrovirus or human foamy virus. Later it became clear that this was a chimpanzee isolate, and human foamy virus is now considered to have resulted from cross-species transmission. It remains the most studied of the foamy viruses and has now been designated the PFV.
Foamy virus genomes share overall organizational similarity with all complex retroviruses; the open reading frames encode three standard retroviral structural proteins for the core, enzymes of replication and virus envelope (Gag, Pol and Env, respectively), as well as accessory viral proteins, all of which are flanked by long terminal repeat (LTR) sequences (Figure 1 ). The 5 0 end dimerization signal suggests that the pre-genomic singlestranded diploid RNA is packaged into the virion, but whereas the RNA is characteristically reverse-transcribed into DNA, before it is integrated into the host genome, the process can also occur late in the viral life cycle, just before budding from the infected cell. Thus, as about 20% of virions contain infectious DNA, foamy viruses can be viewed as DNA viruses that replicate by an RNA intermediate, rather than hepadnaviruses. The full length of the single-stranded DNA genome is 13 Kb, longer than that of MLV (8 kb) or HIV-1 (9 Kb) and, similar to other complex retroviruses, carries additional open reading frames in the 3 0 region of the genome, giving rise to accessory proteins, in this case, Tas (the transcriptional transactivator essential for replication) and, by virtue of a splicing event, Bet, an accessory protein abundantly produced in the infected cell. Unusually, both are transcribed from an internal promoter, located in the env open reading frame, rather than from the promoter in the LTR. The Bet protein, disposable for replication in vitro, is nonetheless expressed in abundance in the infected cell. Its exact function is not clear, although there is a suggestion that it functions in a manner similar to the HIV-1 Vif protein in antagonizing cellular APOBEC3 proteins. 10 It is interesting that Trim-5-alpha can also restrict foamy viruses by sequences in the N-terminal half of Gag.
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As for the ORVs, the LTRs contain cis-acting regulatory elements for viral protein expression. The internal promoter in env has some basal activity, resulting in the expression of the accessory proteins, Tas and Bet. Tas, in turn, is a DNA-binding transcriptional activator that enhances gene expression from the internal promoter but also from the otherwise silent promoter in the U3 region, leading to the expression of the structural proteins. This way, PFV can control gene expression in a temporal manner, something ORVs, such as HIV-1, achieve through alternative splicing. To express their structural proteins, ORVs first generate Gag-Pol fusion proteins that are subsequently cleaved into Gag and Pol that can be further processed. The Gag-Pol fusion proteins also provide a means by which the ORVs encapsidate their Pol protein into virions, as Gag self-assembles. For foamy viruses, Pol is expressed independently from Gag from its own spliced mRNA. A fraction of the PFV Gag proteins is processed by cleaving a 3-kDa peptide from the C-terminus, resulting in a double band of about 71/68 kDa in size. This cleavage is essential for reverse transcription. However, no analogous proteins to matrix, nucleocapsid or capsid is found in mature PFV virions. As the foamy virus Pol is expressed independently from Gag and no Gag-Pol fusion protein is made, this poses the problem of incorporating Pol into the virion. It is thought that regions in cis-acting sequences present on viral RNA that are involved in RNA encapsidation can also bind to Pol. Recently, however, it was shown that Gag, too, contains C-terminal determinants that facilitate encapsidation of Pol into the virions. 12 This independent expression of Pol from a spliced mRNA may be an advantage for vector development, as a vector produced from three separate plasmids encoding each of the structural genes is less likely to undergo recombination. Foamy virus capsids are restricted to the cytoplasm in the absence of its cognate envelope protein and, thus, particles are not released into the supernatant in the absence of it or in the provision of a different envelope. This points to a specific interaction between Gag and its cognate Env, making it difficult to pseudotype foamy virus capsids with Env proteins of other viruses without loss of infectivity. The foamy virus replication cycle (shown in Figure 2 ) bears resemblance to that of the hepadnaviruses. 13 Foamy virus integrates into the host cell in typical retrovirus manner
Integration of the proviral DNA into the host genome is an essential part of the life cycle of every retrovirus and foamy viruses, despite being uniquely different in many respects, are no exception to this. The integration process for retroviruses has been the subject of several studies over recent years and genome-wide analysis of integration has shown that insertion into the host genome is not as random an event as was once thought, but influenced by target DNA sequences. Lentiviruses, such as HIV-1, strongly favour integration into active transcription units. However, the fact that MLV targets transcription start sites and CpG islands, in part explains the leukaemia that developed subsequent to the gene therapy trial for severe combined immunodeficiency-X1, when the MLV vector integrated near the protooncogenes, LMO2 and MDS/Evi1. 14 For foamy viruses, a 15 no foamy virus vector integration sites were found near the LMO2 oncogene and two were present in the MDS1-EviI gene locus. This was significantly less than for gammaretroviral vectors. In ontological studies, the authors found only one class of genes, involved with catabolism, to be overrepresented for insertion of the PFV vector. Again, the relevance of this finding is unclear. Taken together, a comparison of lentivirus and foamy virus integration 16 reveals that lentiviruses integrate preferentially into units of active transcription and that, although all retrovirus vectors will integrate close to proto-oncogenes, PFV does not have a preference for sites within genes, but only a modest preference for transcription start sites and for CpG islands When the detailed mechanism of PFV integration is known, this may offer a further possible advantage over ORVs. The 3D structure of the PFV integrase (IN) core domain has recently been published and in vitro characterization of the enzyme has highlighted the usefuleness of the PFV integrase to detailed structural studies of integration. Although the PFV IN has little sequence homology to the HIV IN, it was still sensitive to lentiviral strand transfer inhibitors, suggesting that these reagents target highly conserved regions of IN-DNA complexes 17 The mechanism of the IN-DNA recognition event is emerging as the functional LTR nucleotides involved become known 18 and the solubility and catalytic efficiency of the PFV IN is established. 19 No integrating vector system can be regarded as completely 'safe' based on its integration profile, and safeguards are needed. To this end, an assay capable of detecting activation of neighbouring genes could be useful. 20, 21 The potential risk of transformation might be reduced by introducing physiological promoters to replace native or other retroviral promoters. 22 There is an additional risk with ORV vectors of a read-through into host sequences, resulting in fusion proteins with unforeseen characteristics, if the termination of transcription at the 3 0 end of the viral genome is not tightly controlled. In feline foamy virus the read-through from the 3 0 LTR into neighbouring genes is a more stringent process, resulting in termination at the 3 0 end 23 and this may hold for PFV as discussed by Rethwilm. 13 Once integration is complete, subsequent gene expression from the integrated genes transported by the vector can be silenced by host factors, switching off continuous expression. This, however, has not occurred in animal models transplanted for over two years with PFV vectors. 24 
Foamy viruses have untapped potential as safe vectors
With the definition of sequences necessary for packaging and regulation of gene expression it became possible to generate foamy virus vectors with minimal cis-acting sequences, that were replication defective, self inactivating and could carry transgenes of up to 9.2 kb in length. With no packaging cell line available, strategies to produce foamy virus vectors depend on transient co-transfection of up to three individual expression cassettes for the structural proteins Gag, Pol and Env and a plasmid encoding the transgene. 25 This minimizes the generation of replication-competent PFV through recombination, improving safety. Replication-defective foamy virus vectors can now be produced consistently at titres of 10 7 ml after concentration, sufficient for ex vivo gene therapy applications, and without detectable helper virus. Similar self-inactivating feline foamy virus virus vectors have been produced that are capable of longterm transduction in cell lines. 23 Foamy virus vectors are more efficient than gammaretroviral vectors in transducing quiescent cells, but unlike lentiviral vectors, they fail to transduce truly resting cells in which foamy viruses accumulate close to the centrosome, but uncoating is impaired. On stimulation, however, disassembly and viral infection proceeds, indicating that uncoating is the rate-limiting step for productive foamy virus infection of growth-arrested cells. 26 For example, quiescent human CD34+ progenitor cells can be transduced by PFV and HIV vectors at a frequency of 40-50%, when transduction was assayed when cells were allowed to cycle. Under these conditions, however, transduction by MLV was only about 5%.
Vectors derived from PFV have been used to deliver transgenes efficiently and transduce a diverse range of cells, including hematopoietic cells in vitro. For example, Sun et al. 27 inhibited hepatitis B virus replication by small interfering RNAs delivered by PFV vectors. Taylor et al. 
Genes delivered by foamy virus vectors in vivo
Chronic granulomatosis disease is a diverse group of hereditory diseases caused most commonly by a defect in the phagocyte nicotinamide adenine dinucleotide phosphate oxidase (PHOX). The affected gene on the X chromosome codes for the gp91 protein, gp91-PHOX. When Sca1+ haematopoeitic stem cells (HSCs) isolated from gene-deficient mice are transduced by PFV vector carrying the PHOX transgene, 40-50% of the cells were transduced, a success rate similar to that achieved by lentiviral vectors. However, replacing the transduced haematopoeitic stem cells in gp91 PHOX-deficient mice was unsuccessful both in our own laboratory and in those of others. This was possibly due to either insufficient vector titre, viability of transfused cells or toxicity when the vector was concentrated. However, in an encouraging single experiment, CD34+ cells transduced with PFV vector containing an enhanced green fluorescent protein (EGFP) expression cassette we found that 15-20% of CD34+ cells expressed the marker 6 weeks after engrafting them into a non-obese diabetic/severe combined immunodeficiency mouse. Since those problematic early experiments, a number of more successful in vivo applications have been reported. When bone marrow cells, transduced with PFV vector expressing the DNA repair protein O 6 -methylguanine DNA methyltransferase were engrafted into mice, complete myeloablative therapy caused death in a proportion of animals. However, mice treated with a sub-myeloablative therapy survived, and up to 55% of them expressed O 6 -methylguanine DNA methyltransferase in 50% of the progeny bone marrow cells for at least one year after transplantation. 31 The fact that foamy virus-mediated gene expression in quiescent stem cells is only possible when the cells are subsequently stimulated to divide raised questions about how effective PFV vectors might be in post-mitotic tissue, such as the brain. Caprariello et al. 32 addressed this by comparing equal titres of foamy and lentiviral vectors in vivo and found that foamy virus vectors were significantly better at transducing brain parenchyma than the lentiviruses. One week after transduction, the PFV transduced area measured 20.5 mm 3 versus 1.17 mm 3 for the lentiviral vector. However, after 8 weeks, the transduced volume of the brain was reduced to 0.521 mm 3 and 0.367 mm 3 for the PFV vector and the lentiviral vector, respectively. The authors suggested that there was a transient phase of virus entry and gene expression but a lack of permanent integration for the foamy virus vector resulting in only 2.5% of the initially transduced volume maintained. By comparison, 31.6% of the volume transduced with the lentiviral vector maintained long-term expression. Liu et al. 33 were of a similar opinion after injecting PFV vector expressing glutamic acid decarboxylase into dorsal root ganglion neuronal cells to attenuate below-injury level central neuropathic pain, after spinal cord injury. Symptoms were reversed after 7 days, reversal lasted for 6 weeks, but re-inoculation with vector was necessary to maintain the restored phenotype for another 6-7 weeks, possibly due to genetic silencing. Si et al. 34 reported on the long-term repopulating activity of Fanconi anaemia FanccÀ/À stem cells in mice after exposure to foamy virus vector, and showed repopulation of primary and secondary recipients. This study successfully used a short (8-14 h) vector exposure time without pre-stimulation, compared with the 4-day gammaretroviral vector protocol that perpetuates a time-dependent increase in apoptosis and a reduction in myeloid progenitors and repopulating ability. Integrated retroviral vectors may change the activity of certain genes, not just by directly inserting into these genes, but also by integration in close proximity to them. Hendrie et al. 20 developed a plasmidbased assay to detect activation of a reporter gene by inserted proviral vectors based on HIV, MLV and FV. In this setting, PFV vectors had a lower propensity to activate the reporter gene than vectors based on HIV or gammaretrovirus, indicating that PFV vectors may be safer in terms of failing to trans-activate neighbouring proto-oncogenes.
Foamy virus vector cure dogs of a genetic disease
The progression of foamy virus vectors towards the goal of therapeutic exploitation will owe much to Russell's ground-breaking work of the last few years that has provided the proof of principle needed pour encourager les autres to consider seriously the therapeutic potential of these vectors. In the first place, his group showed that when CD34+ cells fractionated from PBMCs were transduced by foamy virus vectors expressing an EGFP marker gene and intravenously infused into two dogs, the dogs maintained long-term transgene expression of more than 450 days and 650 days, respectively, in all cells of haematopoietic lineage. Approximately 19% of cells expressed the marker gene. 24 When foamy and lentiviral vectors were compared in two dogs for their ability to transduce long-term haematopoietic repopulating canine cells in vivo, both dogs showed rapid neutrophil and multi-lineage engraftment of transduced cells and a similar level of transgene expression for more than 700 days after engraftment. 35 In one dog the transduction efficiency of the foamy virus vector was 4.5 and 4.7% for lymphocytes and granulocytes, respectively. For the lentivirus vector, initial transduction efficiency was higher (9.5% in lymphocytes and 9.3% in granulocytes), but by day 939 after transplantation had dropped to levels of the foamy virus vector. For the second dog it was found that both vectors transduced lymphocytes and granulocytes at a similar rate of about 2% each. However, the piece de resistance was the reversal of disease phenotype by PFV-mediated gene transfer to repopulating cells in a canine model. Canine leukocyte adhesion deficiency is a rare autosomal recessive condition affecting Irish setters and similar to leukocyte adhesion deficiency in humans. A missense mutation in the beta-2 integrin subunit gene ITGB2 (CD18) resulting in a cysteine to serine change at position 36 of the CD18 subunit of leukocyte adhesion proteins, prevents leukocyte surface expression of the CD11/Cd18 complex. Cell-cell adhesion events are consequently disrupted and granulocytic dysfunction ensues. Dogs with this genetic immunodeficiency die at an early age of severe recurrent bacterial infections, despite administration of massive doses of antibiotics. Treatment of 4-11-week-old canines by infusion of autologous CD34+ haematopoietic stem cells transduced by foamy virus vector carrying the canine CD18 gene corrected the disease state in four out of five dogs without apparent side effects (the death of the fifth dog was unrelated to the treatment). It is impressive that transgene expression was at least three times higher than that in a similar experiment using gammaretroviruses. The healthy state has been maintained for over 3 years, the abnormal lymphocyte proliferation and neutrophil adhesion characteristics of the disease state are now normal, and analysis of virus integration indicates a lower risk of integration near oncogenes compared with gammaretrovirus integration. 15 These dramatic results were the first demonstration of cure of a genetic disease by foamy virus vector therapy in a clinically relevant model and will surely blaze the trail towards clinical trials of human disease.
Prospects
To summarize, foamy virus vectors are not being offered as the panacea for all that is wrong with other vectors and, indeed, we have highlighted some of their disadvantages; an unknown receptor, no available packaging cell lines, an inability to transduce nondividing cells without previous stimulation and cytotoxic proteins at high concentrations, which has curtailed the production of concentrated vector and has possibly been responsible for low engraftment. However, their advantages would seem to outweigh their current disadvantages and their development since the first replication-defective vector less than two decades ago has been staggering, given the handful of research groups world wide dedicated to their investigation. In particular, their safety record and enhanced transduction of haematopoietic, neuronal and mesenchymal 13 progenitor cells bodes well for future clinical exploitation. There is no doubt that the work from Russell's laboratory showing that animals can be cured of a genetic defect using gene therapy based on foamy virus vectors has given a much needed boost to the field. Other laboratories will now be encouraged to put effort into addressing the challenging questions of foamy virus biology knowing that clinical exploitation is an achievable goal. Over the next couple of years, we can expect a two-pronged approach to foamy virus vector development. In the first place, given their safety record and given the similarities between canine leukocyte adhesion deficiency and the human disease, it would not be surprising to see extrapolation from the canine studies into clinical trials. It remains to be seen whether vector titres and the lack of a packaging cell line will be limiting. Simultaneously, a number of laboratories, world -wide, are working towards a greater understanding of foamy virus biology that is likely to overcome both disadvantages.
